DEVELOPING · Attributed source report · science · World

Trial results posted: A Phase 3 Study to Assess the Immune Response and Safety of rMenB+OMV NZ in Primed Healthy Participants (10 to 20 Years Old)

NULLPEN · Source published 11/6/2026, 12:00:00 AM UTC

ClinicalTrials.gov records the first posting of results for study NCT06995430 on 2026-11-06. A registry posting does not establish that a treatment is effective or safe.

Why it matters

New trial results are available for scrutiny. This report describes the posting only; it does not evaluate the findings.

What remains uncertain

The study findings have not been independently assessed by NULLPEN.

The source record

National Library of Medicine, National Institutes of Health

Source: ClinicalTrials.gov, National Library of Medicine, United States. Registry entries are filed by trial sponsors; the registry does not verify them.Retrieved 2026-11-06T17:00:31.446Z. Updated on NULLPEN 2026-11-06T17:00:34.583Z.Revision sha256:1e2ff37d23f73b38bea2c26790bbfd89286b8796caf9d9980d24139b8a81e61d